DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Summary

The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Breast Cancer
• Breast Cancer Female
• Metastatic Triple-Negative Breast Carcinoma
• ER Positive Breast Cancer
• HER2-negative Breast Cancer
• HER2 Negative Breast Carcinoma
• ER-negative Breast Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Nancy Lin, MD

Last updated on ClinicalTrials.gov

August 6, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites